SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-162060"
 

Search: onr:"swepub:oai:DiVA.org:liu-162060" > MRI Assessment of T...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005271naa a2200529 4500
001oai:DiVA.org:liu-162060
003SwePub
008191119s2019 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1620602 URI
0247 a https://doi.org/10.1002/hep.306742 DOI
040 a (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Ajmera, Veeral H.u Univ Calif San Diego Hlth, CA USA4 aut
2451 0a MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial)
264 c 2019-06-18
264 1b WILEY,c 2019
338 a print2 rdacarrier
500 a Funding Agencies|the John A. Hartford Foundation; GALMED; American Association for the Study of Liver Diseases Foundation Clinical and Translational Research Award; Atlantic Philanthropies, Inc.
520 a Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 inhibitor, has been shown to reduce hepatic fat content in patients with primary nonalcoholic fatty liver disease (NAFLD); however, its effect in patients with human immunodeficiency virus (HIV)-associated NAFLD is unknown. The aramchol for HIV-associated NAFLD and lipodystrophy (ARRIVE) trial was a double-blind, randomized, investigator-initiated, placebo-controlled trial to test the efficacy of 12 weeks of treatment with aramchol versus placebo in HIV-associated NAFLD. Fifty patients with HIV-associated NAFLD, defined by magnetic resonance imaging (MRI)-proton density fat fraction (PDFF) amp;gt;= 5%, were randomized to receive either aramchol 600 mg daily (n = 25) or placebo (n = 25) for 12 weeks. The primary endpoint was a change in hepatic fat as measured by MRI-PDFF in colocalized regions of interest. Secondary endpoints included changes in liver stiffness using magnetic resonance elastography (MRE) and vibration-controlled transient elastography (VCTE), and exploratory endpoints included changes in total-body fat and muscle depots on dual-energy X-ray absorptiometry (DXA), whole-body MRI, and cardiac MRI. The mean (+/- standard deviation) of age and body mass index were 48.2 +/- 10.3 years and 30.7 +/- 4.6 kg/m(2), respectively. There was no difference in the reduction in mean MRI-PDFF between the aramchol group at -1.3% (baseline MRI-PDFF 15.6% versus end-of-treatment MRI-PDFF 14.4%, P = 0.24) and the placebo group at -1.4% (baseline MRI-PDFF 13.3% versus end-of-treatment MRI-PDFF 11.9%, P = 0.26). There was no difference in the relative decline in mean MRI-PDFF between the aramchol and placebo groups (6.8% versus 1.1%, P = 0.68). There were no differences in MRE-derived and VCTE-derived liver stiffness and whole-body (fat and muscle) composition analysis by MRI or DXA. Compared to baseline, end-of-treatment aminotransferases were lower in the aramchol group but not in the placebo arm. There were no significant adverse events. Conclusion: Aramchol, over a 12-week period, did not reduce hepatic fat or change body fat and muscle composition by using MRI-based assessment in patients with HIV-associated NAFLD (clinicaltrials.gov ID:NCT02684591).
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng
7001 a Cachay, Edwardu Univ Calif San Diego, CA 92103 USA4 aut
7001 a Ramers, Christianu Family Hlth Ctr, CA USA4 aut
7001 a Vodkin, Irineu Univ Calif San Diego Hlth, CA USA4 aut
7001 a Bassirian, Shirinu Univ Calif San Diego Hlth, CA USA4 aut
7001 a Singh, Seemau Univ Calif San Diego Hlth, CA USA4 aut
7001 a Mangla, Neeraju Univ Calif San Diego Hlth, CA USA4 aut
7001 a Bettencourt, Richeleu Univ Calif San Diego Hlth, CA USA4 aut
7001 a Aldous, Jeannette L.u San Ysidro Hlth, CA USA4 aut
7001 a Park, Danielu San Ysidro Hlth, CA USA4 aut
7001 a Lee, Danielu Univ Calif San Diego, CA 92103 USA4 aut
7001 a Blanchard, Jenniferu Univ Calif San Diego, CA 92103 USA4 aut
7001 a Mamidipalli, Adrijau Univ Calif San Diego, CA 92093 USA4 aut
7001 a Boehringer, Andrewu Univ Calif San Diego, CA 92093 USA4 aut
7001 a Aslam, Saimau Univ Calif San Diego, CA 92103 USA4 aut
7001 a Dahlqvist Leinhard, Olof,d 1978-u Linköpings universitet,Avdelningen för radiologiska vetenskaper,Medicinska fakulteten,Region Östergötland, Radiofysikavdelningen US,AMRA Med AB, Linkoping, Sweden4 aut0 (Swepub:liu)oloda24
7001 a Richards, Lisau Univ Calif San Diego Hlth, CA USA4 aut
7001 a Sirlin, Claude B.u Univ Calif San Diego, CA 92093 USA4 aut
7001 a Loomba, Rohitu Univ Calif San Diego, CA 92093 USA4 aut
7102 a Univ Calif San Diego Hlth, CA USAb Univ Calif San Diego, CA 92103 USA4 org
7730 t Hepatologyd : WILEYg 70:5, s. 1531-1545q 70:5<1531-1545x 0270-9139x 1527-3350
8564 u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164416
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-162060
8564 8u https://doi.org/10.1002/hep.30674

Find in a library

  • Hepatology (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view